Phaleria macrocarpa extract

Drug Profile

Phaleria macrocarpa extract

Alternative Names: DLBS 1425; Phalecarps

Latest Information Update: 07 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dexa Medica
  • Class Antineoplastics; Phytotherapies
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Apoptosis stimulants; Caspase stimulants; Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Breast cancer

Most Recent Events

  • 30 Nov 2012 Dexa Medica Group completes a phase II/III trial in Breast cancer (neoadjuvant therapy) in Indonesia (NCT01433562)
  • 10 Oct 2012 Dexa Medica Group terminates a phase II trial for Breast cancer in Indonesia (NCT01006785)
  • 08 Apr 2012 Dexa Medica Group initiates enrolment in a phase II trial for Breast cancer in Indonesia (NCT01006785)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top